Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)

Plain-language summary

This study evaluates Polyphenon E (epigallocatechin 3 gallate) in patients with dystrophic epidermolysis bullosa, a skin disease. It enrolled patients with a known mutation in the COL7A1 gene, comparing the treatment against placebo. The study was conducted in Phase 2 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 2

Status

Completed

Sponsor

Centre Hospitalier Universitaire de Nice

Intervention

Polyphenon E before Placebo, placebo before treatment

Start date

10/1/2010

Estimated completion

7/1/2013

Countries

France

Related genes

Locations

• Bordeaux, France
• Dijon, France
• Paris, France
• Paris, France
• Toulouse, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* known mutation of COL7A1

Exclusion Criteria:

* tea drinkers
* patient receiving induction treatment,protease inhibitor treatment
* liver failure